Patents Examined by Valerie Rodriguez-Garcia
  • Patent number: 10799470
    Abstract: A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F]-labelled lactate derivative which is [18F]-3-fluoro-2-hydroxypropionic acid: Also, a process for the radiosynthesis of the [18F]-labelled lactate derivative. Further, the use of the [18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: October 13, 2020
    Assignee: GRANDIS
    Inventors: Pierre Sonveaux, Daniel Labar, Vincent Van Hée, Gwenaël Dehon, Raphaël Frédérick
  • Patent number: 10793531
    Abstract: Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP) are also described.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: October 6, 2020
    Assignee: Mironid Limited
    Inventor: Julia Adam
  • Patent number: 10787433
    Abstract: Pyradizine derivatives that activity the excitatory amino acid transporter 2 (EAAT2) of the formula: and methods of use thereof for treating or preventing diseases, disorders, and conditions with glutamate toxicity.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 29, 2020
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., OHIO STATE UNIVERSITY
    Inventors: Kevin Hodgetts, Chien-Liang Glenn Lin
  • Patent number: 10779538
    Abstract: A multifunctional broad spectrum antimicrobial composition is described. The composition can be incorporated into a wood preservative, or used as an additive to provide antimicrobial properties to water-based wood coatings. The composition is a concentrated water-miscible emulsion containing 3-iodo-2-propynyl N-butylcarbamate (IPBC), carbendazim (BCM) and propiconazole (PPCZ), and has antimicrobial activity against a wide variety of fungal organisms, including surface molds, blue stain fungi and wood rotting fungi. The composition can act as an in-can preservative and is useful for antimicrobial protection of wood and wood-based substrates.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 22, 2020
    Assignee: Boss Holdings Inc.
    Inventors: Eric Bos, Nenad Vidovic
  • Patent number: 10759741
    Abstract: A solvent is at least partially separated from a catalyst. The catalyst comprises nickel and a bidentate phosphorus-containing ligand. The method for separation involves distilling a catalyst solution. The ratio of 2-pentenenitrile to 3-pentenenitrile in distillation column bottoms is controlled to reduce the amount of 3-pentenenitrile which is isomerized to form 2-methyl-3-butenenitrile. Isomerization of 3-pentenenitrile to 2-methyl-3-butenenitrile and subsequent isomerization of 2-methyl-3-butenenitrile to 2-methyl-2-butenenitrile, and/or hydrocyanation of 2-methyl-3-butenenitrile to methylglutaronitrile represents a loss in adiponitrile yield in a process for making adiponitrile.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: September 1, 2020
    Assignee: INVISTA North America S.a r.l.
    Inventors: Sudhir N. V. K. Aki, James M. Garner, William J. Tenn, III, Thomas E. Vos
  • Patent number: 10751704
    Abstract: A hydrogenation reaction catalyst used for a reaction of 1,4-anhydroerythritol and hydrogen to produce 3-hydroxytetrahydrofuran includes a carrier, at least one oxide selected from the group consisting of an oxide of a Group 6 element and an oxide of a Group 7 element, the oxide being supported on the carrier, and a metal other than a Group 6 element and a Group 7 element, the other metal being supported on the carrier. The amount of the oxide supported on the carrier in terms of a metal atom forming the oxide is 0.01 to 10% by weight based on the total amount of the oxide and the carrier being 100% by weight. The molar ratio in terms of metal of the other metal to the Group 6 element and Group 7 element forming the oxide [other metal/Group 6 element and Group 7 element] is 50/1 to 1/4.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 25, 2020
    Assignee: DAICEL CORPORATION
    Inventors: Keiichi Tomishige, Yoshinao Nakagawa, Yasuteru Kajikawa, Yuuichirou Hirai
  • Patent number: 10745363
    Abstract: Provided are crystal forms A, B, D, E, F, G and H of valsartan disodium salt and a preparation method therefor.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 18, 2020
    Assignee: NANJING NORATECH PHARMACEUTICALS CO., LTD
    Inventors: Fei Liu, Gang Wu, Weiming Jiang, Cheng-Gang Lin, Xuan Cai, Ping Lin, Yuling Lu, Lixiang Liu
  • Patent number: 10744111
    Abstract: An antibiotic compound of formula (III): or a salt or stereoisomer thereof; wherein R1-R3 and R5-R10 are independently selected from the group consisting of H, alkyl group, substituted alkyl group, halogen, OH, NH2 and SH; R4 is H, alkyl group or substituted alkyl group; X1-X2 are independently selected from the group consisting of ?O, ?S, NH, H, alkyl, halogen, OH, SH and NH2; W is a saturated acyclic hydrocarbon chain of 1 to 15 carbon atoms; and Z is a neutral or positively charged organic group. The compounds are useful in treating bacterial diseases.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 18, 2020
    Inventors: Pavel Dibrov, Elena Dibrov, Grant Pierce
  • Patent number: 10738002
    Abstract: The present invention relates to compounds having a benzotropolone core, and compositions containing said compounds acting as ATG4B inhibitors, thereby inhibiting autophagy. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: August 11, 2020
    Assignees: UNIVERSITAIR ZIEKENHUIS ANTWERPEN, UNIVERSITEIT ANTWERPEN
    Inventors: Koen Augustyns, Matthias Cleenewerck, Guido R. Y. De Meyer, Jurgen Joossens, Ammar Kurdi, Pieter Van Der Veken, Christel Vangestel, Sigrid Stroobants, Wim Martinet
  • Patent number: 10738028
    Abstract: Disclosed are the anti-bacterial activity and the anti-tumor activity of a class of new spiro three-membered ring and spiro five-membered ring peptide deformylase inhibitor. The spiro three-membered ring and spiro five-membered ring peptide deformylase inhibitor of the present invention, as a class of new anti-bacterial agent, are effective against many antibiotic-resistant Gram-positive strains by inhibiting the activity of the peptide deformylase required in the synthesis of bacterial proteins, and do not affect the synthetic process of the main proteins of the human body, thus selectively killing bacteria.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 11, 2020
    Assignee: RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD
    Inventors: Wenhao Hu, Fengping Lv, Yang Tang, Ziyan Li, Chen Chen, Jianhai Wei, Suzhen Dong, Yu Qian
  • Patent number: 10729689
    Abstract: A series of novel EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for inhibitory activity against Rac. Based on modeling studies on EHop-016, compounds with a more rigid structural conformation can mimic this “U-shaped” conformation would improve the anti-migration activity against metastatic cells. Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases, for instance compounds of formula (I) Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: August 4, 2020
    Assignee: UNIVERSITY OF PUERTO RICO
    Inventors: Eliud Hernandez-O'Farrill, Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Linette Castillo-Pichardo
  • Patent number: 10729680
    Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 4, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Marcus Koppitz, Julien Lefranc, Lars Wortmann, Antje Margret Wengner, Gerhard Siemeister, Ulf Bömer, Benjamin Bader, Philip Lienau, Hans Schick
  • Patent number: 10730828
    Abstract: The disclosed subject matter provides N-hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: August 4, 2020
    Assignees: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Vincent Jacob Kalish, Lisa Marie Frost, Frederick Arthur Brookfield, Stephen Martin Courtney, John P. Toscano
  • Patent number: 10722501
    Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 28, 2020
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
  • Patent number: 10710984
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 14, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • Patent number: 10703737
    Abstract: The present invention relates to histone deacetylase inhibitors, and to pharmaceutical compositions comprising the compounds, useful for the treatment of ischemia-reperfusion injury and for cardioprotection.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: July 7, 2020
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Donald R. Menick, Chung-Jen James Chou, Daniel Herr, Xiaoyang Li
  • Patent number: 10696671
    Abstract: The present disclosure relates to novel imidazo[1,2-a]pyridine derivatives, and more particularly to imidazo[1,2-a]pyridine derivatives of Formula 1 wherein Y1, Y2 and Y3 are each independently H, halogen, a C1-C6 straight chain alkyl unsubstituted or substituted with R1, or hydroxy; R1 is hydroxy; Y4 is H, C1-C6 straight chain alkyl, or C1-C6 alkoxy; and X is H or halogen, and having an excellent activity of inhibiting gastric acid secretion, methods for preparing the same, and the use thereof. The imidazo[1,2-a]pyridine derivatives according to the present disclosure have gastric acid secretion inhibitory activity, and thus may be effectively used for the prevention or treatment of gastrointestinal inflammatory diseases or gastric acid-related diseases.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: June 30, 2020
    Assignee: Jeil Pharmaceutical Co., Ltd.
    Inventors: Jeongmin Kim, Hyunho Lee, Kwangwoo Chun, Chun-Ho Park, Eunsung Jang, Yoonsun Park, Joseph Kim
  • Patent number: 10696675
    Abstract: A novel imidazopyridine derivative compound and uses thereof are disclosed.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: June 30, 2020
    Assignee: HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Moon Sub Lee, Eun Young Byun, Ji Sook Kim, Won Jeoung Kim, Nam Du Kim, Seung Hyun Jung, Young Gil Ahn
  • Patent number: 10683288
    Abstract: A compound having the structure:
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 16, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: James Leighton, Stephen Ho, Corinne Foley
  • Patent number: 10682333
    Abstract: The present invention relates to a composition for inhibiting the formation of a SNARE complex, containing myricetin derivatives, and having novel structures and obtained by the acylation of myricetin, laricitrin, combretol, or syringetin. The myricetin derivatives are considered to exhibit an effect of being bioconverted into myricetin in a cell. The myricetin derivatives lost the dark color of conventional myricetin and properties thereof were changed such that the myricetin derivatives have properties of photostability and fat solubility. Therefore, since stable form myricetin derivatives are absorbed into a cell such that an activity, possessed by normal myricetin, of inhibiting the formation of a SNARE complex are exhibited, the present invention can exhibit an excellent function as a SNARE targeting prodrug, and as a composition for inhibiting the formation of a SNARE complex, containing the same.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: June 16, 2020
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Dae Hyuk Kweon, Joon Bum Park, Young Hun Jung, Woo Jae Chung, Pa Ul Heo